Date: May 13, 2022
Attention: Providers
Effective Date: March 29, 2022
Providers should monitor the Texas Children’s Health Plan (TCHP) Provider Portal regularly for alerts and updates associated to the COVID-19 event. TCHP reserves the right to update and/or change this information without prior notice due to the evolving nature of the COVID-19 event.Call to action: On March 29, 2022, the U.S. Food and Drug Administration (FDA) amended the emergency use authorization (EUA) for the Pfizer-BioNTech and Moderna COVID-19 vaccine.
How this impacts providers: On March 29, 2022, the U.S. Food and Drug Administration (FDA) amended the emergency use authorization (EUA) for the Pfizer-BioNTech and Moderna COVID-19 vaccine as follows:
Authorization of a second booster dose for individuals 50 years and older at least 4 months after the first booster dose with any authorized or approved COVID-19 vaccine.
Immunocompromised individuals may receive a second booster at least 4 months after the first booster dose with any authorized or approved COVID-19 vaccine subject to the age-specific limitations for the respective vaccine.
The Pfizer-BioNTech COVID-19 vaccine is indicated for individuals 12 years and older.
The Moderna COVID-19 vaccine is indicated for individuals 18 years and older.